Sir, – Life-saving medicines and drugs are becoming prohibitively expensive, up to a point where this endangers the lives and health of patients.

A lack of transparency around what different countries pay for medicines and the actual cost of researching, developing and manufacturing treatments allows pharmaceutical corporations to charge exorbitant and arbitrary prices. This is a bad deal for both patients and the health systems which care for them. In Ireland, high prices have limited patients’ access to medicines.

This year, the National Centre for Pharmacoeconomics reported that the HSE had almost used its entire annual budget for purchasing new drugs after only three months, and last month it was reported that expensive new cancer drugs would be available only for private patients with VHI cover.

At the World Health Assembly (WHA) in Geneva next week, a resolution aimed at improving transparency in markets for drugs, vaccines and other health-related technologies will be tabled.

If passed, the resolution, which is proposed and supported by 10 countries – including Italy, Spain and Portugal – would make valuable information about prices paid, the cost and price structure of medicines, their quality, safety and effectiveness available for governments. This would significantly strengthen the Irish Government’s negotiating position and enhance its ability to obtain more affordable prices for medicines.

Medicines save lives, keep us healthy and alleviate suffering. There is no reason that governments should wish to remain in the dark on pricing, quality, safety or efficacy when negotiating for something as vital as medicines. Neither should the public be refused access to such important information.

Ireland must help put lives over profit and support the transparency resolution at next week’s World Health Assembly. –

Yours, etc,

Dr KIERAN HARKIN,

Access to Medicines Ireland,

ISABEL SIMPSON,

Director, Médecins Sans Frontières Ireland, AVERIL POWER, CEO, Irish Cancer Society, Dr PADRAIG McGARRY, President, IMO,
STEPHAN McMAHON,
Co-founder, Irish Patients
Association, FINTAN FOY,
CEO, ICGP, PAUL
GILLigan, CEO, St
Patrick's Mental Health
Service, NADINE FERRIS FRANCE, Executive
Director, Irish Forum for
Global Health, ANN
NOLAN, Asst Prof in Global
Health, Trinity Centre for
Global Health, ANTHONY
STAINES, Prof of Health
Systems, DCU, Prof SAM J
Mc CONKEY, Deputy Dean,
RCSI, Dr MARK MURPHY,
Lecturer, RCSI , RONÁN
CONWAY, Prof of Health
Research Methods, RCSI, Dr
KEVIN BROWN, Asst Prof in
Clinical Medicine, TCD,
URSULA Mc CARThY,
Franciscan Missionaries of
St Joseph, HEYDI FOSTER,
CEO, Misean Cara, MARK

CUMMING, Head of

Comhlámh, Sr WINIFRED OJO, Institute leader, Sisters

of St Louis, Dr CIARA CONLON, Universities

Allied for Essential

Medicines, PHIL Ní SHEAGHDHA,

General Secretary Designate, INMO,

C/o Access to Medicines

Ireland, Dublin 2.

READ MORE

- Manhattan sale blocked
- An Irish welcome for Donald Trump
- Delay and denial of vote in elections
- Skin colour versus gender
- Boycotting the Eurovision in Israel

Be part of the conversation. Subscribe.

MORE FROM THE IRISH TIMES

Kathy Sheridan: Trump has already reduced Britain to vassal status

Opinion
Nationalism and unionism are becoming less relevant in the North

Opinion
Germany's politics is threatening its role in Europe

Opinion
1989 will be remembered for Beijing and not Berlin